Tirzepatide for Sleep Apnea: SURMOUNT-OSA & FDA Approval

Obstructive sleep apnea (OSA) - repeated pauses in breathing during sleep caused by blocked upper airways - affects approximately one billion people worldwide, with 60 to 70 percent of patients also living with obesity. For decades, treatment options were limited to mechanical devices like CPAP machines (face masks worn at night that keep the airways open with a gentle stream of pressurized air). This has changed: tirzepatide (brand name Zepbound) has become the first medication approved by the U.S. Food and Drug Administration (FDA) for moderate-to-severe OSA in adults with obesity. The approval is based on the Phase 3 SURMOUNT-OSA trial.

What does the SURMOUNT-OSA trial show?

The multicenter, randomized, double-blind trial - run at multiple hospitals, with participants randomly assigned to groups, and neither doctors nor patients knowing who got the drug versus placebo - evaluated tirzepatide (10 mg or 15 mg weekly) over 52 weeks in 469 participants across two arms: patients not using CPAP therapy (Study 1) and those on CPAP (Study 2). The results are striking:

• Study 1 (no CPAP): Tirzepatide reduced the apnea-hypopnea index (AHI) - the standard measure for sleep apnea, which counts how often per hour of sleep breathing pauses or becomes very shallow - by a mean of 25.3 events per hour, versus 5.3 with placebo - corresponding to roughly a 56 percent reduction from baseline (placebo: about 9 percent).
• Study 2 (with CPAP): Tirzepatide lowered AHI by 29.3 events per hour (placebo: 5.5).
• Disease remission (meaning the symptoms had largely disappeared): After 52 weeks, 42 percent (Study 1) and 50 percent (Study 2) of tirzepatide-treated patients achieved remission or only mild OSA.

The findings were published in the New England Journal of Medicine (Malhotra et al., 2024) and presented at the American Diabetes Association's 84th Scientific Sessions.

FDA approval and EMA position

The FDA granted approval in December 2024 - the first pharmacological treatment option for OSA ever. The agency emphasized that tirzepatide should be used alongside a reduced-calorie diet and increased physical activity. In the EU, the CHMP (Committee for Medicinal Products for Human Use) adopted a corresponding opinion on Mounjaro on 11 December 2025. The EMA, however, did not consider a separate OSA indication necessary, as use in OSA with obesity is already covered by the existing weight management indication: OSA is listed in the product information as a weight-related health problem within the obesity indication.

Clinical significance

This approval marks a paradigm shift: for the first time, a medication directly targets the underlying obesity and significantly reduces OSA severity. Experts like Dr. Louis Aronne (Weill Cornell Medicine) consider the combination of tirzepatide with CPAP the optimal strategy for OSA patients with obesity. For more details on mechanism and evidence, visit the tirzepatide page.

Important: Tirzepatide is a prescription medication. The SURMOUNT-OSA trial shows that not all patients respond equally - follow-up sleep studies are recommended. Also read the article on retatrutide, the next candidate from the GIP/GLP-1 family - a group of drugs that includes tirzepatide and that acts on gut hormones such as GLP-1, GIP, and glucagon to influence appetite and metabolism.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. If you suspect sleep apnea or are considering tirzepatide treatment, please consult a healthcare professional.